Stockscreener 앱 받기
89.73
1.62%
1.43
시장 영업 전:
93.72
3.99
+4.45%
전일 마감가:
$88.30
열려 있는:
$89.81
하루 거래량:
512.02K
Relative Volume:
0.57
시가총액:
$5.40B
수익:
$360.35M
순이익/손실:
$-149.57M
주가수익비율:
-30.31
EPS:
-2.96
순현금흐름:
$-81.27M
1주 성능:
-5.07%
1개월 성능:
-12.25%
6개월 성능:
-31.86%
1년 성능:
-9.32%
1일 변동 폭
$88.14
$90.50
1주일 범위
$86.16
$92.98
52주 변동 폭
$77.91
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
명칭
Glaukos Corporation
전화
949-367-9600
주소
1 GLAUKOS WAY, ALISO VIEJO, CA
GKOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
89.73 | 5.40B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 개시 | Truist | Buy |
| 2023-11-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-14 | 재개 | Stephens | Overweight |
| 2022-10-04 | 개시 | Needham | Buy |
| 2022-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2022-02-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2021-11-03 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-12-09 | 개시 | Oppenheimer | Perform |
| 2020-11-17 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 개시 | Jefferies | Hold |
| 2020-03-05 | 개시 | Citigroup | Sell |
| 2020-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-01-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2019-12-12 | 다운그레이드 | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 개시 | BTIG Research | Neutral |
| 2018-08-30 | 개시 | Berenberg | Hold |
| 2018-08-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 재확인 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-04-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-03-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-01-06 | 업그레이드 | Stifel | Hold → Buy |
| 2016-10-27 | 개시 | Wells Fargo | Outperform |
모두보기
Glaukos Corporation 주식(GKOS)의 최신 뉴스
Gel Stent Market Size, Share & Trends Analysis Report 2025-2032 | Allergan, Alcon, Innfocus and Glaukos Corp. - openPR.com
Glaukos Buys OC Office for $16.6M - Orange County Business Journal
First Week of June 20th Options Trading For Glaukos (GKOS) - Nasdaq
Glaukos Announces the Release of its 2024 Sustainability Report - GuruFocus
Lobbying Update: $45,000 of GLAUKOS CORPORATION lobbying was just disclosed - Nasdaq
Forecasting The Future: 7 Analyst Projections For Glaukos - Benzinga
(GKOS) Long Term Investment Analysis - news.stocktradersdaily.com
Stifel cuts Glaukos stock target to $140, maintains buy rating - Investing.com Australia
Stifel cuts Glaukos stock target to $140, maintains buy rating By Investing.com - Investing.com Canada
Glaukos (GKOS) Price Target Reduced by Stifel Amid Flat iDose Volumes | GKOS Stock News - GuruFocus
Glaukos (GKOS) Price Target Reduced by Mizuho Amid Q1 Outlook | GKOS Stock News - GuruFocus
Piper Sandler cuts Glaukos stock price target to $165 By Investing.com - Investing.com Canada
AVEDRO, INC. SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Avedro, Inc. (AVDR) Over the Proposed Merger of the Company with Glaukos Corporation - marketscreener.com
Piper Sandler cuts Glaukos stock price target to $165 - Investing.com
Piper Sandler Adjusts Glaukos (GKOS) Price Target Amid Stock Dec - GuruFocus
Glaukos (GKOS) Sees Price Target Reduction as MedTech Sector Fac - GuruFocus
Truist Adjusts Price Target for Glaukos (GKOS) Ahead of Q1 Repor - GuruFocus
Glaukos price target lowered to $140 from $185 at Truist - TipRanks
Figure 1. iStent inject GTS 400 (Glaukos Corporation, San Clemente, CA)... - ResearchGate
Keratoconus Therapeutics Market Size in 7MM is expected to grow - openPR.com
Gel Stent Market Generated Opportunities, Future Scope 2025-2032 | Allergan, Alcon, Innfocus and Glaukos Corp. - openPR.com
Glaukos to Release First Quarter 2025 Financial Results after Ma - GuruFocus
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 - BioSpace
What Makes Glaukos Corporation (GKOS) a Compelling Stock? - Insider Monkey
Glaukos: Macro Environment & Limited Market Access Could Stunt Growth Plans (NYSE:GKOS) - Seeking Alpha
Glaukos stock plunge confirms InvestingPro’s February overvaluation warning By Investing.com - Investing.com Australia
Glaukos stock touches 52-week low at $91.65 amid market shifts By Investing.com - Investing.com South Africa
Glaukos stock touches 52-week low at $91.65 amid market shifts - Investing.com Australia
Glaukos Corp (GKOS) Stock Price Up 2.95% on Apr 2 - GuruFocus
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Learn to Evaluate (GKOS) using the Charts - news.stocktradersdaily.com
Glaukos CFO Thurman Alex R. sells $162k in stock By Investing.com - Investing.com South Africa
Glaukos CFO Thurman Alex R. sells $162k in stock - Investing.com India
Glaukos Corporation (NYSE:GKOS) Is Expected To Breakeven In The Near Future - simplywall.st
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - Yahoo Finance
Primecap Management Co. CA Has $182.08 Million Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
First Week of May 16th Options Trading For Glaukos (GKOS) - Nasdaq
(GKOS) Trading Report - Stock Traders Daily
Glaukos, RadiusXR, and Topcon Healthcare Work to Advance Vision Testing - Medical Product Outsourcing
RadiusXR and Glaukos Announce a New Collaboration With Topcon Healthcare, Inc., and the Launch of Inspire - Vision Monday
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
Glaukos Corporation (GKOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
자본화:
|
볼륨(24시간):